Follow
roberta pica
roberta pica
Responsabile IBD Unit - Ospedale Sandro Pertini Roma
Verified email at aslroma2.it
Title
Cited by
Cited by
Year
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease
G Monteleone, MF Neurath, S Ardizzone, A Di Sabatino, MC Fantini, ...
New England Journal of Medicine 372 (12), 1104-1113, 2015
4732015
Azathioprine or methotrexate in the treatment of patients with steroid‐dependent or steroid‐resistant ulcerative colitis: results of an open‐label study on efficacy and …
OA Paoluzi, R Pica, A Marcheggiano, P Crispino, F Iacopini, C Iannoni, ...
Alimentary pharmacology & therapeutics 16 (10), 1751-1759, 2002
1652002
Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis.
M Boirivant, R Pica, R DeMaria, R Testi, F Pallone, W Strober
The Journal of clinical investigation 98 (11), 2616-2622, 1996
1641996
Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients
M Zippi, C Corrado, R Pica, EV Avallone, C Cassieri, D De Nitto, ...
World journal of gastroenterology: WJG 20 (46), 17463, 2014
1422014
2‐Week Triple Therapy for Helicobacter pylori Infection is Better Than 1‐Week in Clinical Practice: a Large Prospective Single‐Center Randomized Study
P Paoluzi, F Iacopini, P Crispino, F Nardi, A Bella, M Rivera, P Rossi, ...
Helicobacter 11 (6), 562-568, 2006
1132006
Anti-tissue transglutaminase antibodies in inflammatory bowel disease: new evidence
MD Tola, L Sabbatella, MC Anania, A Viscido, R Caprilli, R Pica, ...
Clinical Chemistry and Laboratory Medicine (CCLM) 42 (10), 1092-1097, 2004
992004
Inter-observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD)
M Daperno, M Comberlato, F Bossa, L Biancone, AG Bonanomi, ...
Digestive and Liver Disease 46 (11), 969-973, 2014
962014
Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1‐year follow‐up study
OA Paoluzi, F Iacopini, R Pica, P Crispino, A Marcheggiano, A Consolazio, ...
Alimentary pharmacology & therapeutics 21 (9), 1111-1119, 2005
912005
Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects
MC Di Paolo, OA Paoluzi, R Pica, F Iacopini, P Crispino, M Rivera, ...
Digestive and Liver Disease 33 (7), 563-569, 2001
912001
Safety of treatments for inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
L Biancone, V Annese, S Ardizzone, A Armuzzi, E Calabrese, F Caprioli, ...
Digestive and Liver Disease 49 (4), 338-358, 2017
562017
Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis
R Pica, OA Paoluzi, F Iacopini, A Marcheggiano, P Crispino, M Rivera, ...
Inflammatory bowel diseases 10 (6), 731-736, 2004
522004
Diffuse febrile dermatosis in a patient with active ulcerative colitis under treatment with steroids and azathioprine: a case of Sweet’s syndrome: case report and review of …
OA Paoluzi, P Crispino, A Amantea, R Pica, F Iacopini, A Consolazio, ...
Digestive and liver disease 36 (5), 361-366, 2004
512004
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study
S Vermeire, PL Lakatos, T Ritter, S Hanauer, B Bressler, R Khanna, ...
The Lancet Gastroenterology & Hepatology 7 (1), 28-37, 2022
502022
Training programs on endoscopic scoring systems for inflammatory bowel disease lead to a significant increase in interobserver agreement among community gastroenterologists
M Daperno, M Comberlato, F Bossa, A Armuzzi, L Biancone, ...
Journal of Crohn's and Colitis 11 (5), 556-561, 2017
472017
Biological therapy for dermatological manifestations of inflammatory bowel disease
M Zippi, R Pica, D De Nitto, P Paoluzi
World Journal of Clinical Cases: WJCC 1 (2), 74, 2013
46*2013
One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication
F Iacopini, P Crispino, OA Paoluzi, A Consolazio, R Pica, M Rivera, ...
Digestive and liver disease 37 (8), 571-576, 2005
462005
Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial
P Paoluzi, G d'Albasio, A Pera, GB Porro, OA Paoluzi, R Pica, M Cottone, ...
Digestive and Liver Disease 34 (11), 787-793, 2002
412002
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
G Fiorino, F Caprioli, M Daperno, F Mocciaro, M Principi, A Viscido, ...
Digestive and Liver Disease 51 (5), 632-639, 2019
402019
Role of desmoplasia in recurrence of stage II colorectal cancer within five years after surgery and therapeutic implication
P Crispino, G De Toma, A Ciardi, A Bella, M Rivera, G Cavallaro, ...
Cancer investigation 26 (4), 419-425, 2008
362008
IL-13 mRNA tissue content identifies two subsets of adult ulcerative colitis patients with different clinical and mucosa-associated microbiota profiles
A Butera, M Di Paola, F Vitali, D De Nitto, F Covotta, F Borrini, R Pica, ...
Journal of Crohn's and Colitis 14 (3), 369-380, 2020
342020
The system can't perform the operation now. Try again later.
Articles 1–20